{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:56:48Z","timestamp":1791867408476,"version":"4.3.4"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s44313-025-00107-0","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:01:30Z","timestamp":1762182090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Unveiling the role of microRNAs, the PI3K\/AKT pathway, and their associations in various types of leukemia: a comprehensive review"],"prefix":"10.1007","volume":"60","author":[{"given":"Amir Modarresi","family":"Chahardehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esfandiar","family":"Mali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Afrooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirmasoud","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Khalaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed Soleimani","family":"Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hananeh Esmaeil","family":"Beygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Mohagheghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Khanbabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heliya","family":"Haghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arefnezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rezaei-Tazangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"107_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","author":"J O'Brien","year":"2018","unstructured":"O\u2019Brien J, et al. Overview of microrna biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018. https:\/\/doi.org\/10.3389\/fendo.2018.00402.","journal-title":"Front Endocrinol"},{"key":"107_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1385632","author":"A Modarresi Chahardehi","year":"2024","unstructured":"Modarresi Chahardehi A, et al. Micrornas and angiosarcoma: are there promising reports? Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1385632.","journal-title":"Front Oncol"},{"key":"107_CR3","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fnins.2024.1513095","volume":"18","author":"SSM Hosseininasab","year":"2025","unstructured":"Hosseininasab SSM, et al. Alzheimer\u2019s disease and infectious agents: a comprehensive review of pathogenic mechanisms and microRNA roles. Front Neurosci. 2025;18:2024.","journal-title":"Front Neurosci."},{"issue":"1","key":"107_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ijlh.14211","volume":"46","author":"R Chandraprabha Vineetha","year":"2024","unstructured":"Chandraprabha Vineetha R, et al. Microrna-based therapies: revolutionizing the treatment of acute myeloid leukemia. Int J Lab Hematol. 2024;46(1):33\u201341.","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"107_CR5","first-page":"94","volume":"18","author":"R Arefnezhad","year":"2024","unstructured":"Arefnezhad R, et al. Function of MicroRNAs in normal and abnormal ovarian activities: a review focus on MicroRNA-21.\". Int J Fertil Steril. 2024;18(2):94\u2013112.","journal-title":"Int J Fertil Steril"},{"issue":"6","key":"107_CR6","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1021\/acsomega.2c07885","volume":"8","author":"F Arshad","year":"2023","unstructured":"Arshad F, et al. Comparative expression analysis of Breakpoint cluster region-Abelson oncogene in leukemia patients. ACS Omega. 2023;8(6):5975\u201382.","journal-title":"ACS Omega"},{"issue":"2","key":"107_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.62347\/WDWE6603","volume":"15","author":"MA Karimi","year":"2025","unstructured":"Karimi MA, et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL: a systematic review and meta-analysis. Am J Blood Res. 2025;15(2):9\u201319.","journal-title":"Am J Blood Res"},{"issue":"8","key":"107_CR8","doi-asserted-by":"publisher","first-page":"e0306962","DOI":"10.1371\/journal.pone.0306962","volume":"19","author":"KW Kang","year":"2024","unstructured":"Kang KW, et al. Use of extracellular vesicle microRNA profiles in patients with acute myeloid leukemia for the identification of novel biomarkers. PLoS ONE. 2024;19(8):e0306962.","journal-title":"PLoS ONE"},{"key":"107_CR9","doi-asserted-by":"publisher","first-page":"1374068","DOI":"10.3389\/fimmu.2024.1374068","volume":"15","author":"A Witalisz-Siepracka","year":"2024","unstructured":"Witalisz-Siepracka A, et al. STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance. Front Immunol. 2024;15:1374068.","journal-title":"Front Immunol"},{"key":"107_CR10","unstructured":"Pillai, P.M. and W.L. Carroll, Chapter 18 - Acute lymphoblastic leukemia, in Lanzkowsky's Manual of Pediatric Hematology and Oncology (Seventh Edition), J.D. Fish, J.M. Lipton, and P. Lanzkowsky, Editors. 2022, Academic Press. p. 413\u2013438."},{"key":"107_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225822","author":"K Ito","year":"2021","unstructured":"Ito K, Ito K. Leukemia stem cells as a potential target to achieve therapy-free remission in chronic myeloid leukemia. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13225822.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"107_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7150\/ijbs.86305","volume":"20","author":"J Sun","year":"2024","unstructured":"Sun J, et al. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci. 2024;20(1):175\u201381.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"107_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41375-023-02095-5","volume":"38","author":"H Playa-Albinyana","year":"2024","unstructured":"Playa-Albinyana H, et al. Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation. Leukemia. 2024;38(3):557\u201369.","journal-title":"Leukemia"},{"issue":"1","key":"107_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41420-024-02068-2","volume":"10","author":"A Turk","year":"2024","unstructured":"Turk A, et al. Multiple omics levels of chronic lymphocytic leukemia. Cell Death Discov. 2024;10(1):293.","journal-title":"Cell Death Discov"},{"issue":"4","key":"107_CR15","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1002\/jcb.27918","volume":"120","author":"N El-Khazragy","year":"2019","unstructured":"El-Khazragy N, et al. miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia. J Cell Biochem. 2019;120(4):6315\u201321.","journal-title":"J Cell Biochem"},{"key":"107_CR16","doi-asserted-by":"publisher","first-page":"1612702","DOI":"10.1155\/2022\/1612702","volume":"2022","author":"M Du","year":"2022","unstructured":"Du M, et al. The global burden of leukemia and its attributable factors in 204 countries and territories: findings from the Global Burden of Disease 2019 Study and projections to 2030. J Oncol. 2022;2022:1612702.","journal-title":"J Oncol"},{"issue":"12","key":"107_CR17","first-page":"2541","volume":"52","author":"BS Amiri","year":"2023","unstructured":"Amiri BS, et al. Evaluation of MicroRNA as Minimal Residual Disease in Leukemia: Diagnostic and Prognostic Approach: A Review. Iran J Public Health. 2023;52(12):2541\u201353.","journal-title":"Iran J Public Health"},{"key":"107_CR18","doi-asserted-by":"publisher","first-page":"115115","DOI":"10.1016\/j.biopha.2023.115115","volume":"165","author":"J Yang","year":"2023","unstructured":"Yang J, et al. Microrna-488: a mirna with diverse roles and clinical applications in cancer and other human diseases. Biomed Pharmacother. 2023;165:115115.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"107_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.blre.2016.11.003","volume":"31","author":"Q Fernandes","year":"2017","unstructured":"Fernandes Q. MicroRNA: defining a new niche in leukemia. Blood Rev. 2017;31(3):129\u201338.","journal-title":"Blood Rev"},{"issue":"3","key":"107_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bjhh.2017.03.006","volume":"39","author":"FM Furtado","year":"2017","unstructured":"Furtado FM, et al. Comparison of microrna expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia. Rev Bras Hematol Hemoter. 2017;39(3):237\u201343.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"107_CR21","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce CM. The role of micrornas in human cancer. Signal Transduct Target Ther. 2016;1:15004.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"107_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.13043","volume":"167","author":"K Lin","year":"2014","unstructured":"Lin K, et al. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. Br J Haematol. 2014;167(3):346\u201355.","journal-title":"Br J Haematol"},{"issue":"10","key":"107_CR23","doi-asserted-by":"publisher","first-page":"e30545","DOI":"10.1002\/pbc.30545","volume":"70","author":"Y Xue","year":"2023","unstructured":"Xue Y, et al. PI3K\/AKT pathway-related microRNA variants in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023;70(10):e30545.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"107_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.31083\/j.fbl2802037","volume":"28","author":"J Zhong","year":"2023","unstructured":"Zhong J, et al. To investigate the occurrence and development of colorectal cancer based on the PI3K\/AKT\/mTOR signaling pathway. Front Biosci (Landmark Ed). 2023;28(2):37.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"107_CR25","doi-asserted-by":"publisher","first-page":"111279","DOI":"10.1016\/j.biopha.2021.111279","volume":"137","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, et al. The emerging role of non-coding RNAs in the regulation of PI3K\/AKT pathway in the carcinogenesis process. Biomed Pharmacother. 2021;137:111279.","journal-title":"Biomed Pharmacother"},{"key":"107_CR26","doi-asserted-by":"publisher","first-page":"119984","DOI":"10.1016\/j.lfs.2021.119984","volume":"285","author":"M Akbarzadeh","year":"2021","unstructured":"Akbarzadeh M, et al. Crosstalk between miRNA and PI3K\/AKT\/mTOR signaling pathway in cancer. Life Sci. 2021;285:119984.","journal-title":"Life Sci"},{"key":"107_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020412","author":"VE Sanchez","year":"2019","unstructured":"Sanchez VE, et al. Targeting PI3K signaling in acute lymphoblastic leukemia. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20020412.","journal-title":"Int J Mol Sci"},{"key":"107_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","volume":"698","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai S, et al. The relation between PI3K\/AKT signalling pathway and cancer. Gene. 2019;698:120\u20138.","journal-title":"Gene"},{"issue":"16","key":"107_CR29","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.3390\/cancers13163949","volume":"13","author":"F Rascio","year":"2021","unstructured":"Rascio F, et al. The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review. Cancers. 2021;13(16):3949.","journal-title":"Cancers"},{"issue":"9","key":"107_CR30","doi-asserted-by":"publisher","first-page":"e0329560","DOI":"10.1371\/journal.pone.0329560","volume":"20","author":"J Zhang","year":"2025","unstructured":"Zhang J, et al. TRIM6 affects the prognosis of acute myeloid leukemia through the PI3K\/AKT signaling pathway and is associated with immune infiltration. PLoS ONE. 2025;20(9):e0329560.","journal-title":"PLoS ONE"},{"key":"107_CR31","unstructured":"Missiroli, S. INVOLVEMENT AND ROLE OF THE PI3K\/AKT NETWORK IN DIFFERENT TYPES OF LEUKEMIA CELLS BEFORE AND AFTER IN VITRO TREATMENT WITH CONVENTIONAL OR NEWLY DEVELOPED DRUGS. 2009."},{"key":"107_CR32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-120089","author":"X Haowen","year":"2018","unstructured":"Haowen X, et al. Haploinsufficiency for NR3C1 drives glucocorticoid resistance by inactivation the PI3K\/AKT\/GSK3\u03b2\/Bim pathway in adult acute lymphoblastic leukemia. Blood. 2018. https:\/\/doi.org\/10.1182\/blood-2018-99-120089.","journal-title":"Blood"},{"issue":"5","key":"107_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/1874467215666220516143155","volume":"16","author":"G Asgaritarghi","year":"2023","unstructured":"Asgaritarghi G, et al. Anti-cancer role of dendrosomal nano solanine in chronic myelogenous leukemia cell line through attenuation of PI3K\/AKT\/mTOR signaling pathway and inhibition of hTERT Expression. Curr Mol Pharmacol. 2023;16(5):592\u2013608.","journal-title":"Curr Mol Pharmacol"},{"issue":"2","key":"107_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3892\/or.2020.7888","volume":"45","author":"P Zhang","year":"2021","unstructured":"Zhang P, et al. Involvement of Blnk and Foxo1 in tumor suppression in BCR-ABL1-transformed pro-B cells. Oncol Rep. 2021;45(2):693\u2013705.","journal-title":"Oncol Rep"},{"key":"107_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010215","author":"GP Amarante-Mendes","year":"2022","unstructured":"Amarante-Mendes GP, et al. BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14010215.","journal-title":"Pharmaceutics"},{"key":"107_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092934","author":"S Darici","year":"2020","unstructured":"Darici S, et al. Targeting PI3K\/Akt\/mTOR in AML: rationale and clinical evidence. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9092934.","journal-title":"J Clin Med"},{"issue":"5","key":"107_CR37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"P Sophie","year":"2010","unstructured":"Sophie P, et al. Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95(5):819\u201328.","journal-title":"Haematologica"},{"issue":"1","key":"107_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13023-021-01929-8","volume":"16","author":"G Canaud","year":"2021","unstructured":"Canaud G, et al. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021;16(1):306.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"107_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3324\/haematol.2009.010785","volume":"95","author":"N Chapuis","year":"2010","unstructured":"Chapuis N, et al. Autocrine IGF-1\/IGF-1R signaling is responsible for constitutive PI3K\/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica. 2010;95(3):415\u201323.","journal-title":"Haematologica"},{"issue":"4","key":"107_CR40","doi-asserted-by":"publisher","first-page":"e23725","DOI":"10.1002\/jcla.23725","volume":"35","author":"E Roshandel","year":"2021","unstructured":"Roshandel E, et al. PI3 kinase signaling pathway in hematopoietic cancers: a glance in miRNA\u2019s role. J Clin Lab Anal. 2021;35(4):e23725.","journal-title":"J Clin Lab Anal"},{"key":"107_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082907","author":"I Nepstad","year":"2020","unstructured":"Nepstad I, et al. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21082907.","journal-title":"Int J Mol Sci"},{"key":"107_CR42","first-page":"102220","volume":"44","author":"M Malekan","year":"2025","unstructured":"Malekan M, et al. Inhibition of PI3K\/AKT\/mTOR signaling enhances autophagy in HL-60 acute myeloid leukemia cells: an integrative bioinformatic and in vitro study. Biochem Biophys Rep. 2025;44:102220.","journal-title":"Biochem Biophys Rep"},{"issue":"2","key":"107_CR43","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1080\/21655979.2021.2024327","volume":"13","author":"S Zhang","year":"2022","unstructured":"Zhang S, et al. 2-methoxyestradiol combined with ascorbic acid facilitates the apoptosis of chronic myeloid leukemia cells via the microRNA-223\/Fms-like tyrosine kinase 3\/phosphatidylinositol-3 kinase\/protein kinase B axis. Bioengineered. 2022;13(2):3470\u201385.","journal-title":"Bioengineered"},{"key":"107_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215297","author":"W Wiese","year":"2023","unstructured":"Wiese W, et al. PI3K\/Akt\/mTOR signaling pathway in blood malignancies-new therapeutic possibilities. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15215297.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"107_CR45","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"S Park","year":"2010","unstructured":"Park S, et al. Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95(5):819\u201328.","journal-title":"Haematologica"},{"key":"107_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","volume":"59","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani AS. PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125\u201332.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"107_CR47","doi-asserted-by":"publisher","first-page":"737","DOI":"10.32598\/bcn.2021.1693.1","volume":"12","author":"F Saadat","year":"2021","unstructured":"Saadat F, et al. The repression of matrix metalloproteinases and cytokine secretion in glioblastoma by targeting K+ channel. Basic Clin Neurosci. 2021;12(6):737\u201344.","journal-title":"Basic Clin Neurosci"},{"issue":"7","key":"107_CR48","first-page":"1310","volume":"48","author":"F Safavifar","year":"2019","unstructured":"Safavifar F, et al. Augmented cAMP signaling by co-administration of Resveratrol and Curcumin: a cellular biosensor kinetic assessment. Iran J Public Health. 2019;48(7):1310\u20136.","journal-title":"Iran J Public Health"},{"key":"107_CR49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23539","author":"F Ye","year":"2017","unstructured":"Ye F. Microrna expression and activity in T-cell acute lymphoblastic leukemia. Oncotarget. 2017. https:\/\/doi.org\/10.18632\/oncotarget.23539.","journal-title":"Oncotarget"},{"key":"107_CR50","doi-asserted-by":"publisher","first-page":"154792","DOI":"10.1016\/j.prp.2023.154792","volume":"250","author":"V Asghariazar","year":"2023","unstructured":"Asghariazar V, et al. Microrna-143 as a potential tumor suppressor in cancer: an insight into molecular targets and signaling pathways. Pathol Res Pract. 2023;250:154792.","journal-title":"Pathol Res Pract"},{"key":"107_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092415","author":"Y Ma","year":"2021","unstructured":"Ma Y, et al. The roles of the let-7 family of micrornas in the regulation of cancer stemness. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10092415.","journal-title":"Cells"},{"key":"107_CR52","doi-asserted-by":"publisher","first-page":"153303382312123","DOI":"10.1177\/15330338231212309","volume":"22","author":"J Xia","year":"2023","unstructured":"Xia J, et al. Meta-analysis of the prognostic value of microRNA-22 in leukemia patients. Technol Cancer Res Treat. 2023;22:15330338231212308.","journal-title":"Technol Cancer Res Treat"},{"key":"107_CR53","doi-asserted-by":"crossref","unstructured":"Alsheikh T. et al. Twenty novel nsSNPs may affect FLT3 gene leading to Acute Myeloid Leukemia (AML) using in silico analysis. bioRxiv, 2023.","DOI":"10.1101\/2023.06.24.546344"},{"issue":"17","key":"107_CR54","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1182\/blood-2015-04-639062","volume":"126","author":"Z Li","year":"2015","unstructured":"Li Z, et al. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015;126(17):2005\u201315.","journal-title":"Blood"},{"issue":"1","key":"107_CR55","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1038\/s41467-021-26420-7","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, et al. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nat Commun. 2021;12(1):6154.","journal-title":"Nat Commun"},{"issue":"4","key":"107_CR56","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/leu.2016.279","volume":"31","author":"N Narayan","year":"2017","unstructured":"Narayan N, et al. Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia. Leukemia. 2017;31(4):808\u201320.","journal-title":"Leukemia"},{"issue":"10","key":"107_CR57","doi-asserted-by":"publisher","first-page":"10375","DOI":"10.1007\/s13277-014-2359-1","volume":"35","author":"M Hashemi","year":"2014","unstructured":"Hashemi M, et al. Association of functional polymorphism at the miR-502-binding site in the 3\u2019 untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report. Tumour Biol. 2014;35(10):10375\u20139.","journal-title":"Tumour Biol"},{"issue":"1","key":"107_CR58","doi-asserted-by":"publisher","first-page":"12089","DOI":"10.1038\/s41598-020-69103-x","volume":"10","author":"DK Choi","year":"2020","unstructured":"Choi DK, et al. The histone lysine methyltransferase SETD8 regulates angiogenesis through HES-1 in human umbilical vein endothelial cells. Sci Rep. 2020;10(1):12089.","journal-title":"Sci Rep"},{"key":"107_CR59","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-G\u00f3mez, Y., et al., miRNAs in acute lymphoblastic leukemia: diagnosis, prognosis and target therapeutic. Advances in Hematologic Malignancies, 2019: p. 57.","DOI":"10.5772\/intechopen.84318"},{"key":"107_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065436","author":"DK Mendiola-Soto","year":"2023","unstructured":"Mendiola-Soto DK, et al. MiRNAs in hematopoiesis and acute lymphoblastic leukemia. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065436.","journal-title":"Int J Mol Sci"},{"key":"107_CR61","unstructured":"Becerra, E.B. and G. Garc\u00eda-Alcocer, MicroRNAs and Their Role in Acute Lymphoblastic Leukemia. Acute Leukemias, 2020."},{"key":"107_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010119","author":"D Barrios-Palacios","year":"2023","unstructured":"Barrios-Palacios D, et al. The role of miRNAs in childhood acute lymphoblastic leukemia relapse and the associated molecular mechanisms. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms25010119.","journal-title":"Int J Mol Sci"},{"key":"107_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/1875692118666200106113610","volume":"17","author":"MH Elias","year":"2020","unstructured":"Elias MH, Nordin N, Hamid NA. In silico study of potential cross-kingdom plant microRNA based regulation in chronic myeloid leukemia. Curr Pharmacogenomics Person Med. 2020;17:125\u201332.","journal-title":"Curr Pharmacogenomics Person Med"},{"key":"107_CR64","first-page":"100257","volume":"16","author":"F Keramati","year":"2021","unstructured":"Keramati F, et al. Circulating miRNAs can serve as potential diagnostic biomarkers in chronic myelogenous leukemia patients. Leuk Res Rep. 2021;16:100257.","journal-title":"Leuk Res Rep"},{"issue":"1","key":"107_CR65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-4598-10-41","volume":"10","author":"K Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","unstructured":"Machov\u00e1 Pol\u00e1kov\u00e1 K, et al. Expression patterns of micrornas associated with CML phases and their disease related targets. Mol Cancer. 2011;10(1):41.","journal-title":"Mol Cancer"},{"issue":"2","key":"107_CR66","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3892\/or.2015.4456","volume":"35","author":"C Di Stefano","year":"2016","unstructured":"Di Stefano C, et al. The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review). Oncol Rep. 2016;35(2):614\u201324.","journal-title":"Oncol Rep"},{"key":"107_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512471","author":"F Autore","year":"2023","unstructured":"Autore F, et al. Role of micrornas in chronic lymphocytic leukemia. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241512471.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"107_CR68","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3892\/mmr.2013.1599","volume":"8","author":"X-X Zhou","year":"2013","unstructured":"Zhou X-X, Wang X. Role of micrornas in chronic lymphocytic leukemia (Review). Mol Med Rep. 2013;8(3):719\u201325.","journal-title":"Mol Med Rep"},{"issue":"1","key":"107_CR69","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-015-0112-x","volume":"8","author":"V Balatti","year":"2015","unstructured":"Balatti V, Pekarky Y, Croce CM. Role of microrna in chronic lymphocytic leukemia onset and progression. J Hematol Oncol. 2015;8(1):12.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"107_CR70","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0377-1237(17)30745-1","volume":"53","author":"YV Sharma","year":"1997","unstructured":"Sharma YV. Clinical utility of beta 2 microglobulin measurement. Med J Armed Forces India. 1997;53(4):249\u201350.","journal-title":"Med J Armed Forces India"},{"issue":"25","key":"107_CR71","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1080\/14767058.2021.1918667","volume":"35","author":"SZ Jalali","year":"2022","unstructured":"Jalali SZ, Enteshari M, Saadat F. Reciprocal assessment of urinary beta-2-microglobulin and BUN levels in renal dysfunction of neonates with birth asphyxia. J Matern Fetal Neonatal Med. 2022;35(25):6624\u201330.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"10","key":"107_CR72","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12032-023-02161-z","volume":"40","author":"P Singh","year":"2023","unstructured":"Singh P. Microrna based combinatorial therapy against TKIs resistant CML by inactivating the PI3K\/Akt\/mTOR pathway: a review. Med Oncol. 2023;40(10):300.","journal-title":"Med Oncol"},{"issue":"4","key":"107_CR73","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3892\/ol.2021.12588","volume":"21","author":"LC Yao","year":"2021","unstructured":"Yao LC, et al. Four potential micrornas affect the progression of pancreatic ductal adenocarcinoma by targeting MET via the PI3K\/AKT signaling pathway. Oncol Lett. 2021;21(4):326.","journal-title":"Oncol Lett"},{"issue":"12","key":"107_CR74","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","volume":"72","author":"J Bertacchini","year":"2015","unstructured":"Bertacchini J, et al. Targeting PI3K\/AKT\/mTOR network for treatment of leukemia. Cell Mol Life Sci. 2015;72(12):2337\u201347.","journal-title":"Cell Mol Life Sci"},{"key":"107_CR75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2015.11.016","volume":"41","author":"SJ Fan","year":"2016","unstructured":"Fan SJ, et al. miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia. Leuk Res. 2016;41:62\u201370.","journal-title":"Leuk Res"},{"issue":"2","key":"107_CR76","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","volume":"111","author":"PG Longo","year":"2008","unstructured":"Longo PG, et al. The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111(2):846\u201355.","journal-title":"Blood"},{"issue":"5","key":"107_CR77","doi-asserted-by":"publisher","first-page":"e10859","DOI":"10.1371\/journal.pone.0010859","volume":"5","author":"N Bar","year":"2010","unstructured":"Bar N, Dikstein R. Mir-22 forms a regulatory loop in PTEN\/AKT pathway and modulates signaling kinetics. PLoS ONE. 2010;5(5):e10859.","journal-title":"PLoS ONE"},{"issue":"6","key":"107_CR78","doi-asserted-by":"publisher","first-page":"e1659","DOI":"10.1002\/wrna.1659","volume":"12","author":"A Favero","year":"2021","unstructured":"Favero A, et al. The many facets of miR-223 in cancer: oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response. Wiley Interdiscip Rev RNA. 2021;12(6):e1659.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"12","key":"107_CR79","doi-asserted-by":"publisher","first-page":"118826","DOI":"10.1016\/j.bbamcr.2020.118826","volume":"1867","author":"L Yang","year":"2020","unstructured":"Yang L, et al. Mir-7 mediates mitochondrial impairment to trigger apoptosis and necroptosis in Rhabdomyosarcoma. Biochimica et Biophysica Acta (BBA). 2020;1867(12):118826.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"4","key":"107_CR80","doi-asserted-by":"publisher","first-page":"189366","DOI":"10.1016\/j.bbcan.2025.189366","volume":"1880","author":"S Ansari","year":"2025","unstructured":"Ansari S, Verma M. Mirna expression based modulation: a new paradigm for the treatment of chronic myeloid leukemia. Biochim Biophys Rev Cancer. 2025;1880(4):189366.","journal-title":"Biochim Biophys Rev Cancer"},{"issue":"1","key":"107_CR81","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","volume":"44","author":"MTD Martino","year":"2025","unstructured":"Martino MTD, Tagliaferri P, Tassone P. Microrna in cancer therapy: breakthroughs and challenges in early clinical applications. J Exp Clin Cancer Res. 2025;44(1):126.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"107_CR82","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.18632\/aging.101991","volume":"11","author":"JD Zhou","year":"2019","unstructured":"Zhou JD, et al. Microrna-335\/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K\/Akt signaling pathway in acute myeloid leukemia. Aging (Albany NY). 2019;11(10):3376\u201391.","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"107_CR83","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ijlh.13742","volume":"44","author":"Y Wu","year":"2022","unstructured":"Wu Y, et al. Circ_0009910 sponges miR-491-5p to promote acute myeloid leukemia progression through modulating B4GALT5 expression and PI3K\/AKT signaling pathway. Int J Lab Hematol. 2022;44(2):320\u201332.","journal-title":"Int J Lab Hematol"},{"key":"107_CR84","doi-asserted-by":"crossref","unstructured":"Wisnik A, et al. Role of MicroRNAs in Acute Myeloid Leukemia. Genes (Basel), 2025;16(4).","DOI":"10.3390\/genes16040446"},{"key":"107_CR85","doi-asserted-by":"publisher","first-page":"114455","DOI":"10.1016\/j.bcp.2021.114455","volume":"196","author":"VM Olkkonen","year":"2022","unstructured":"Olkkonen VM. The emerging roles of OSBP-related proteins in cancer: impacts through phosphoinositide metabolism and protein-protein interactions. Biochem Pharmacol. 2022;196:114455.","journal-title":"Biochem Pharmacol"},{"key":"107_CR86","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5260","author":"J Huang","year":"2021","unstructured":"Huang J, et al. Microrna-93 knockdown inhibits acute myeloid leukemia cell growth via inactivating the PI3K\/AKT pathway by upregulating DAB2. Int J Oncol. 2021. https:\/\/doi.org\/10.3892\/ijo.2021.5260.","journal-title":"Int J Oncol"},{"issue":"4","key":"107_CR87","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/leu.2013.291","volume":"28","author":"ZX Yan","year":"2014","unstructured":"Yan ZX, et al. Microrna187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia. 2014;28(4):880\u20137.","journal-title":"Leukemia"},{"issue":"4","key":"107_CR88","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2018.198267","volume":"104","author":"R Bernardoni","year":"2019","unstructured":"Bernardoni R, et al. A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia. Haematologica. 2019;104(4):717\u201328.","journal-title":"Haematologica"},{"issue":"4","key":"107_CR89","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1182\/blood-2011-02-336487","volume":"118","author":"A Meenhuis","year":"2011","unstructured":"Meenhuis A, et al. MiR-17\/20\/93\/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. Blood. 2011;118(4):916\u201325.","journal-title":"Blood"},{"key":"107_CR90","doi-asserted-by":"publisher","first-page":"109523","DOI":"10.1016\/j.abb.2023.109523","volume":"736","author":"N Lu","year":"2023","unstructured":"Lu N, et al. TET1-mediated microRNA-188-5p promoter hydroxymethylation regulates PTEN\/PI3K\/AKT signaling pathway in acute myeloid leukemia cells. Arch Biochem Biophys. 2023;736:109523.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"107_CR91","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1080\/21691401.2019.1608221","volume":"47","author":"YJ Tian","year":"2019","unstructured":"Tian YJ, et al. Long noncoding RNA SBF2-AS1 act as a ceRNA to modulate cell proliferation via binding with miR-188-5p in acute myeloid leukemia. Artif Cells Nanomed Biotechnol. 2019;47(1):1730\u20137.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"107_CR92","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ebiom.2018.01.031","volume":"28","author":"J Wang","year":"2018","unstructured":"Wang J, et al. High expression of TET1 predicts poor survival in cytogenetically normal acute myeloid leukemia from two cohorts. EBioMedicine. 2018;28:90\u20136.","journal-title":"EBioMedicine"},{"issue":"1","key":"107_CR93","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cellsig.2013.09.021","volume":"26","author":"EC Hales","year":"2014","unstructured":"Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of \u03b3-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal. 2014;26(1):149\u201361.","journal-title":"Cell Signal"},{"issue":"6","key":"107_CR94","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1002\/jcp.29429","volume":"235","author":"C Evangelisti","year":"2020","unstructured":"Evangelisti C, et al. Targeting Wnt\/\u03b2-catenin and PI3K\/Akt\/mTOR pathways in T-cell acute lymphoblastic leukemia. J Cell Physiol. 2020;235(6):5413\u201328.","journal-title":"J Cell Physiol"},{"key":"107_CR95","doi-asserted-by":"publisher","first-page":"11637","DOI":"10.2147\/OTT.S231750","volume":"12","author":"C Yue","year":"2019","unstructured":"Yue C, et al. DUXAP8 a pan-cancer prognostic marker involved in the molecular regulatory mechanism in hepatocellular carcinoma: a comprehensive study based on data mining, bioinformatics, and in vitro validation. Onco Targets Ther. 2019;12:11637\u201350.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"107_CR96","doi-asserted-by":"publisher","first-page":"375","DOI":"10.7150\/jca.21044","volume":"9","author":"Y He","year":"2018","unstructured":"He Y, et al. MiR-149 in human cancer: a systemic review. J Cancer. 2018;9(2):375\u201388.","journal-title":"J Cancer"},{"issue":"5","key":"107_CR97","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/kjm2.12352","volume":"37","author":"Z Ling","year":"2021","unstructured":"Ling Z, et al. The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p\/Reelin mediation of the PI3K\/AKT\/mTOR signaling pathway. Kaohsiung J Med Sci. 2021;37(5):392\u2013401.","journal-title":"Kaohsiung J Med Sci"},{"issue":"Pt A","key":"107_CR98","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.biocel.2016.06.007","volume":"77","author":"S Agatheeswaran","year":"2016","unstructured":"Agatheeswaran S, Chakraborty S. MEF2C and CEBPA: possible co-regulators in chronic myeloid leukemia disease progression. Int J Biochem Cell Biol. 2016;77(Pt A):165\u201370.","journal-title":"Int J Biochem Cell Biol"},{"issue":"7","key":"107_CR99","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2012.339","volume":"27","author":"S Agatheeswaran","year":"2013","unstructured":"Agatheeswaran S, et al. BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia. Leukemia. 2013;27(7):1578\u201380.","journal-title":"Leukemia"},{"issue":"21","key":"107_CR100","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1182\/blood-2008-11-189407","volume":"113","author":"B Stamatopoulos","year":"2009","unstructured":"Stamatopoulos B, et al. Microrna-29c and microrna-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009;113(21):5237\u201345.","journal-title":"Blood"},{"issue":"4","key":"107_CR101","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/CAD.0000000000001019","volume":"32","author":"Y Han","year":"2021","unstructured":"Han Y, Ma Z. Lncrna highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p\/MCL1 axis. Anticancer Drugs. 2021;32(4):427\u201336.","journal-title":"Anticancer Drugs"},{"key":"107_CR102","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.gene.2017.01.004","volume":"607","author":"Y Lu","year":"2017","unstructured":"Lu Y, et al. Long noncoding RNA HULC promotes cell proliferation by regulating PI3K\/AKT signaling pathway in chronic myeloid leukemia. Gene. 2017;607:41\u20136.","journal-title":"Gene"},{"issue":"1","key":"107_CR103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40659-017-0133-8","volume":"50","author":"X Zhang","year":"2017","unstructured":"Zhang X, et al. Mir-22 suppresses tumorigenesis and improves radiosensitivity of breast cancer cells by targeting Sirt1. Biol Res. 2017;50(1):27.","journal-title":"Biol Res"},{"issue":"3","key":"107_CR104","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12288-016-0694-7","volume":"33","author":"KA Dehkordi","year":"2017","unstructured":"Dehkordi KA, et al. Inhibition of MicroRNA miR-222 with LNA inhibitor can reduce cell proliferation in B chronic lymphoblastic leukemia. Indian J Hematol Blood Transfus. 2017;33(3):327\u201332.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"107_CR105","doi-asserted-by":"publisher","first-page":"8","DOI":"10.33808\/clinexphealthsci.1279724","volume":"15","author":"E Mehtero\u011flu","year":"2025","unstructured":"Mehtero\u011flu E, et al. MiR-7-5p may inhibit AML cell proliferation via SKP2, KLF4, OGT target genes. Clin Exp Health Sci. 2025;15(1):8\u201314.","journal-title":"Clin Exp Health Sci"},{"key":"107_CR106","doi-asserted-by":"publisher","first-page":"9214130","DOI":"10.1155\/2022\/9214130","volume":"2022","author":"K Yu","year":"2022","unstructured":"Yu K, et al. MiR-338-3p plays a significant role in casticin-induced suppression of acute myeloid leukemia via targeting PI3K\/Akt pathway. BioMed Res Int. 2022;2022:9214130.","journal-title":"BioMed Res Int"},{"key":"107_CR107","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/171299","author":"J Xiao","year":"2023","unstructured":"Xiao J, et al. Tumor suppressor miR-520a inhibits cell growth by negatively regulating PI3K\/AKT signaling pathway in acute myeloid leukemia. Adv Clin Exp Med. 2023. https:\/\/doi.org\/10.17219\/acem\/171299.","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"107_CR108","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10020-021-00393-1","volume":"27","author":"H Cheng","year":"2021","unstructured":"Cheng H, et al. Human mesenchymal stem cells derived exosomes inhibit the growth of acute myeloid leukemia cells via regulating miR-23b-5p\/TRIM14 pathway. Mol Med. 2021;27(1):128.","journal-title":"Mol Med"},{"key":"107_CR109","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.2147\/OTT.S244813","volume":"13","author":"D Wang","year":"2020","unstructured":"Wang D, et al. MiR-188-5p promotes tumor growth by targeting CD2AP through PI3K\/AKT\/mTOR signaling in children with acute promyelocytic leukemia. Onco Targets Ther. 2020;13:6681\u201397.","journal-title":"Onco Targets Ther"},{"key":"107_CR110","doi-asserted-by":"publisher","first-page":"773601","DOI":"10.3389\/fonc.2022.773601","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, et al. Targeting the lncRNA DUXAP8\/miR-29a\/PIK3CA network restores doxorubicin chemosensitivity via PI3K-AKT-mTOR signaling and synergizes with inotuzumab ozogamicin in chemotherapy-resistant B-cell acute lymphoblastic leukemia. Front Oncol. 2022;12:773601.","journal-title":"Front Oncol"},{"issue":"14","key":"107_CR111","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1080\/10428194.2020.1811269","volume":"61","author":"X Zhou","year":"2020","unstructured":"Zhou X, et al. Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562\/ADM cells. Leuk Lymphoma. 2020;61(14):3451\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"107_CR112","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1158\/1535-7163.MCT-19-0051","volume":"18","author":"ZY Nie","year":"2019","unstructured":"Nie ZY, et al. Morin inhibits proliferation and induces apoptosis by modulating the miR-188-5p\/PTEN\/AKT regulatory pathway in CML cells. Mol Cancer Ther. 2019;18(12):2296\u2013307.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"107_CR113","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/leu.2014.158","volume":"29","author":"F Palacios","year":"2015","unstructured":"Palacios F, et al. Activation of the PI3K\/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia. 2015;29(1):115\u201325.","journal-title":"Leukemia"},{"key":"107_CR114","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","volume":"313","author":"SWL Lee","year":"2019","unstructured":"Lee SWL, et al. Microrna delivery through nanoparticles. J Control Release. 2019;313:80\u201395.","journal-title":"J Control Release"},{"issue":"1","key":"107_CR115","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12951-025-03528-2","volume":"23","author":"N Sanadgol","year":"2025","unstructured":"Sanadgol N, et al. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. J Nanobiotechnology. 2025;23(1):453.","journal-title":"J Nanobiotechnology"},{"issue":"14","key":"107_CR116","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.7150\/ijms.102123","volume":"21","author":"H Qian","year":"2024","unstructured":"Qian H, et al. Decoding the promise and challenges of miRNA-based cancer therapies: an essential update on miR-21, miR-34, and miR-155. Int J Med Sci. 2024;21(14):2781\u201398.","journal-title":"Int J Med Sci"},{"issue":"1","key":"107_CR117","doi-asserted-by":"publisher","first-page":"12","DOI":"10.26555\/eshr.v7i1.11332","volume":"7","author":"Y Khakpour","year":"2025","unstructured":"Khakpour Y, et al. Anaemia and caesarean section in Caucasian race: assessment of risk factors and management strategies. Epidemiol Soc Health Rev. 2025;7(1):12\u201324.","journal-title":"Epidemiol Soc Health Rev"},{"issue":"21","key":"107_CR118","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1182\/blood.V116.21.4914.4914","volume":"116","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, et al. LNA anti-Microrna-155: a novel therapeutic strategy in Waldenstrom macroglobulinemia and chronic lymphocytic leukemia. Blood. 2010;116(21):4914.","journal-title":"Blood"},{"issue":"4","key":"107_CR119","doi-asserted-by":"publisher","first-page":"100556","DOI":"10.1016\/j.jgeb.2025.100556","volume":"23","author":"S Pandey","year":"2025","unstructured":"Pandey S, Yadav P. Exploring the therapeutic potential of micrornas: targeted gene regulation strategies for enhanced cancer therapy. J Genet Eng Biotechnol. 2025;23(4):100556.","journal-title":"J Genet Eng Biotechnol"},{"issue":"17\u201318","key":"107_CR120","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1089\/hum.2024.113","volume":"35","author":"S Brillante","year":"2024","unstructured":"Brillante S, Volpe M, Indrieri A. Advances in MicroRNA therapeutics: from preclinical to clinical studies. Hum Gene Ther. 2024;35(17\u201318):628\u201348.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"107_CR121","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00262-025-04011-5","volume":"74","author":"G Sareen","year":"2025","unstructured":"Sareen G, et al. A new era of cancer immunotherapy: vaccines and miRNAs. Cancer Immunol Immunother. 2025;74(5):163.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"107_CR122","doi-asserted-by":"publisher","first-page":"e99010062","DOI":"10.14440\/jbm.2025.0001","volume":"12","author":"I Kyriakidis","year":"2025","unstructured":"Kyriakidis I, Pelagiadis I, Stiakaki E. Pre-analytical considerations for microRNA quantification in childhood leukemia research. J Biol Methods. 2025;12(2):e99010062.","journal-title":"J Biol Methods"},{"issue":"4","key":"107_CR123","first-page":"265","volume":"35","author":"V Singh","year":"2024","unstructured":"Singh V, et al. Microrna significance in cancer: an updated review on diagnostic, prognostic, and therapeutic perspectives. EJIFCC. 2024;35(4):265\u201384.","journal-title":"EJIFCC"},{"issue":"1","key":"107_CR124","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41525-024-00424-w","volume":"9","author":"I Ellson","year":"2024","unstructured":"Ellson I, et al. MiRNA expression as outcome predictor in pediatric AML: systematic evaluation of a new model. NPJ Genom Med. 2024;9(1):40.","journal-title":"NPJ Genom Med"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00107-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00107-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00107-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:02:50Z","timestamp":1762185770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00107-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["107"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00107-0","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}